Frequency Therapeutics’ (FREQ) Buy Rating Reiterated at Cowen
Cowen restated their buy rating on shares of Frequency Therapeutics (NASDAQ:FREQ) in a research report released on Monday, AnalystRatings.com reports.
Several other research firms have also recently weighed in on FREQ. JPMorgan Chase & Co. assumed coverage on Frequency Therapeutics in a report on Monday, October 28th. They issued an overweight rating and a $25.00 price target on the stock. ValuEngine cut Frequency Therapeutics from a buy rating to a hold rating in a report on Thursday, November 14th. Finally, Goldman Sachs Group assumed coverage on Frequency Therapeutics in a report on Monday, October 28th. They issued a buy rating and a $30.00 price target on the stock.
FREQ traded up $0.32 during trading on Monday, reaching $16.82. 90,557 shares of the company were exchanged, compared to its average volume of 118,250. Frequency Therapeutics has a 12-month low of $11.17 and a 12-month high of $17.44.
In other Frequency Therapeutics news, insider James E. Flynn purchased 285,714 shares of the stock in a transaction on Monday, October 7th. The shares were purchased at an average price of $12.67 per share, with a total value of $3,619,996.38. Also, Director Marc A. Cohen purchased 17,857 shares of the stock in a transaction on Monday, October 7th. The stock was acquired at an average cost of $12.84 per share, for a total transaction of $229,283.88.
About Frequency Therapeutics
Frequency Therapeutics, Inc, a clinical-stage biotechnology company, focuses on harnessing the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. Its Progenitor Cell Activation approach, uses combinations of small molecules to activate progenitor cells within the body to create functional tissue.
Featured Article: Hang Seng Index (HSI)
Receive News & Ratings for Frequency Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Frequency Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.